The abstract is read at the publisher; the summary is JClub's.
Interarterial tenecteplase after successful thrombectomy is linked to higher 90-day mRS 0–1 rates in ANGEL-TNK patients with eTICI 2b50–3 reperfusion (44.8% vs 19.5%).
- Why it matters: Prior thrombectomy plus intraarterial thrombolysis trials have shown inconsistent efficacy, so it is unclear which reperfusion grades benefit and which may face added bleeding risk.
- What they did: In a prespecified post hoc analysis of the multicenter ANGEL-TNK randomized open-label trial, anterior circulation LVO patients received TNK 0.125 mg/kg or standard care after eTICI 2b50–3, stratified into eTICI 2b50–67 and eTICI 2c–3.
- The result: TNK improved mRS 0–1 at 90 days only for eTICI 2b50–67 (RR 2.08, P=0.001), while in eTICI 2c–3 it increased any intracranial hemorrhage within 48 hours (33.3% vs 20.0%, P=0.032) without raising symptomatic ICH or 90-day death.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.